Regression of mucosal melanoma following intralesional talimogene laherparepvec (T-VEC) injection in combination with immunotherapy

J Dtsch Dermatol Ges. 2019 Mar;17(3):321-323. doi: 10.1111/ddg.13763. Epub 2019 Jan 30.

Authors

Christina Drescher¹, Konstantin Drexler¹, Hermann Hilber², Barbara Schmidt³, Sebastian Haferkamp¹

Affiliations

¹ Department of Dermatology, University Medical Center, Regensburg, Germany.
² Department of Ear, Nose and Throat Medicine, University Medical Center, Regensburg, Germany.
³ Institute of Clinical Microbiology and Hygiene, University Medical Center, Regensburg, Germany.

PMID: 30698924
DOI: 10.1111/ddg.13763

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antineoplastic Agents, Immunological / administration & dosage*
Biological Products / administration & dosage*
Combined Modality Therapy
Female
Herpesvirus 1, Human
Humans
Immunotherapy / methods*
Injections, Intralesional
Maxillary Sinus Neoplasms / drug therapy*
Melanoma / drug therapy*
Middle Aged
Nasal Mucosa

Substances

Antineoplastic Agents, Immunological
Biological Products
talimogene laherparepvec